SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around token burns tied to watcher milestones, fueling excitement and perceived scarcity. Talk centers on the strong community, the potential for significant upside, and a desire to reach number one on trending lists. The coin is built on the Solana network and the community is anticipating airdrop details.

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Pump.fun

$PUMP.X is trending as traders discuss its potential, recent website updates, and community takeover of creator rewards, driving bullish sentiment. Conversations revolve around potential breakout points, with community members calling for it to reach penny status. The coin is associated with the meme coin launchpad Pump.fun on the Solana network.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending amid community discussions around a potential breakout and anticipation for news related to its partnership with Nvidia ($NVDA). Some traders speculate about a possible acquisition, while others are focused on insider trading activity and the impact of the new CEO, Chris Allexandre, on the company's future direction in AI data centers.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending as community members highlight its strong ties to the Injective ecosystem and anticipate significant gains. The conversation is driven by Injective's increasing traction and potential ETF, with many believing $NONJA.X offers leveraged exposure to $INJ's growth. Community members emphasize $NONJA.X's unique features, such as its strong community, burned liquidity, and potential for high returns.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR.X) is trending amidst mixed community sentiment, with some touting its infrastructure role in Web3 and the potential of its new L1 Neura blockchain for developers, while others express strong dissatisfaction, labeling it a long-term scam and criticizing its price performance compared to other crypto assets. The core debate revolves around the token's utility and the team's ability to deliver tangible value for holders versus its promise as a foundational element for the decentralized web. Discussions also involve broader themes around infrastructure versus hype-driven crypto investments.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to concerns about production timelines for their Gravity SUV and the overall company's profitability, reflected in negative sentiment from some investors. Despite a recent commercial spot during an NFL game and news of accelerated Gravity SUV production, some community members express skepticism about Lucid's financial future and the effectiveness of the reverse stock split. Discussions also involve potential future funding from Saudi PIF and comparisons to other EV manufacturers like Tesla and Rivian.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA.X) is trending amid anticipation for its mainnet launch and excitement surrounding its potential to revolutionize traditional finance. Community members highlight Keeta's anchor technology and partnerships as key drivers for unifying blockchains. The recent listing on exchanges like Coinbase is also fueling positive sentiment, with some suggesting it will replace other blockchains.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending as investors digest mixed signals, including commentary around tariffs and a potential shift towards energy project ownership. Community members are actively debating the impact of government policies and comparing CSIQ's valuation to peers. Bullish sentiment highlights the company's potential in a growing solar market, while bears express concern over debt and profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced encouraging data from a cancer drug trial.The company reported final survival data from a Phase 2a trial of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">CAN-2409</a> in advanced lung cancer patients who did not respond well to immune checkpoint inhibitors (ICI).&nbsp;The median overall survival (mOS) was 24.5 months for those receiving two courses of CAN-2409, significantly higher than the 9.8-11.8 months seen in similar patients receiving standard chemotherapy.The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.&nbsp;Patients with non-squamous non-small cell lung cancer (NSCLC) showed the most potent response, with a mOS of 25.4 months in this group. Biomarker analysis indicated a stronger immune response in these patients than in those with squamous NSCLC.The treatment also appeared to induce a systemic immune response, as 69% of patients with multiple tumors saw reductions in untreated lesions.&nbsp;CAN-2409 maintained a favorable safety profile throughout the extended follow-up period, the company added.The news sent message volume about Candel on Stocktwits soaring by over 120%, with sentiment climbing further within the ‘neutral’ territory (53/100) from a day ago.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CADL_sentiment_and_message_volume_as_of_Macrh_26_png_1c49d17460.webp" alt="CADL sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>CADL sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One optimistic user said CAN-2409 "is worth billions," adding that Candel also had successful phase-3 trials in prostate cancer and a successful phase-2 in pancreatic cancer.<stembedurl>https://stocktwits.com/strategicmind/message/609387743</stembedurl>Another compared Candel to small-cap biotech firms that were acquired by established pharma giants such as Gilead and Pfizer for tens of billions of dollars, saying the company “will join this GOAT rodeo in no time.”<stembedurl>https://stocktwits.com/chrundel/message/609386559</stembedurl>“I could see this becoming [the] standard of care for adenocarcinoma of the lung,” said another user based on the data.<stembedurl>https://stocktwits.com/Uromaster/message/609354605</stembedurl>Last month, Candel shared updated survival data from Phase 2a trials of CAN-2409 in pancreatic cancer.&nbsp;Meanwhile, Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is expected in the fourth quarter of 2025, and the company plans to submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 2026.Candel stock is down about 12% this year but has gained more than 390% in the past 12 months.&nbsp;According to Koyfin, three out of four analysts covering Candel rate it ‘buy’ while one recommends a ‘strong buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 

Equity

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 


Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a bullish call from Wall Street.Canaccord initiated coverage on the stock with a ‘Buy’ rating and a $20 price target, implying a 91% upside from the last close.&nbsp;The research firm expects continued clinical success for Candel’s lead asset, CAN-2409, in prostate, pancreatic, and non-small cell lung cancer.&nbsp;In testing so far, CAN-2409 has shown a significant increase in median overall survival. If this trend continues, it could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.&nbsp;On Stocktwits, sentiment turned ‘extremely bullish’ on Wednesday as message volume jumped by 50% and new followers increased by 4%.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CADL_sentiment_and_message_volume_Feb_19_d3c9416772.png" alt="CADL sentiment and message volume Feb 19.png" width="1316" height="316"><figcaption>CADL sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>Traders speculated that upcoming data could drive a major rally, with some predicting that strong results from the pancreatic study could push shares into the $30-$40 range.<stembedurl>https://stocktwits.com/Xanderzzzzzzz/message/604910450</stembedurl><stembedurl>https://stocktwits.com/drizz/message/604899234</stembedurl>Last week, BofA Securities also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-surges-on-bofa-buy-call/chPzAKRRtG">initiated</a> coverage on Candel with a ‘Buy’ rating and a $15 price target, citing promising early data for CAN-2409 and CAN-3110 as key drivers of its bullish outlook.&nbsp;The research firm noted that CAN-2409’s early results in prostate cancer suggest a potential breakthrough, while CAN-3110 has shown signs of nearly doubling overall survival in patients with recurrent high-grade glioma.Candel has outlined several key milestones ahead.&nbsp;Updated overall survival data from Phase 2a trials of CAN-2409 in pancreatic and non-small cell lung cancer is expected in the first quarter of 2025.&nbsp;Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is set for the fourth quarter of 2025, while a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer is targeted for the fourth quarter of 2026.<a href="https://stocktwits.com/symbol/CADL">Candel stock</a> is up more than 22% this year. Short interest was 6.2% as of last week, down from 14.1% at the start of the year, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice

CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst. 

Shares of Mullen Automotive Inc. (MULN) plunged nearly 28% on Wednesday, hitting new record lows after quarterly results showed widening losses that further dented retail investor confidence.The struggling EV maker reported first-quarter (Q1) revenue of $2.9 million, stating that it produced more revenue this quarter than in the past two fiscal years combined.&nbsp;However, net losses ballooned by over 46%, with a net loss of $114.9 million attributable to common shareholders after preferred dividends.While adjusted losses per share narrowed to $661.33 from $91,940.42 a year earlier, the company noted that this figure accounted for retroactive reverse stock splits, including a 1:60 split that took <a href="https://stocktwits.com/news-articles/markets/equity/muln-stock-slides-on-reverse-split-plan/ch5icstRHs">effect</a> this week.&nbsp;Most losses were non-cash expenses totaling $91 million, making up 79% of the quarter's total loss.CEO David Michery tried to highlight a positive milestone, saying that $4.4 million worth of invoices were issued and $6 million in vehicle payments were received, marking Mullen's strongest quarter to date.&nbsp;The company's Bollinger segment completed the sale of 20 units, generating $2.8 million in revenue.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CVNA_sentiment_and_message_volume_Feb_19_d795e38b8c.png" alt="CVNA sentiment and message volume Feb 19.png" width="1318" height="324"><figcaption>CVNA sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment turned 'extremely bearish,' with message volume ticking up as traders weighed Mullen's financial strain.One user pointed to Mullen's crippling balance sheet, noting that the company already owed a lot of money to GEM Group from a lost arbitration case."This is an insolvent company," the user concluded.<stembedurl>https://stocktwits.com/KendallP/message/604814133</stembedurl>Another skeptical trader mocked potential buyers.<stembedurl>https://stocktwits.com/FourFingerFred/message/604807224</stembedurl>Mullen in December submitted a modified plan to the U.S. Department of Energy (DOE) seeking $55 million in matching funds to support U.S.-based battery and pack production.&nbsp;Additionally, the company has implemented cost-cutting measures, reducing headcount and personnel costs by $13 million annually.However, <a href="https://stocktwits.com/symbol/MULN">MULN stock</a> has lost over 99% of its value in the past year, reflecting a sharp decline in investor confidence amid legal hurdles, financial distress, and lackluster sales growth.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bear Market and falling chart - stock photo

Mullen's Stock Plumbs New Depths After Q1 Net Loss Balloons By 46%, Retail Traders Throw In The Towel

Most losses were non-cash expenses totaling $91 million, making up 79% of the quarter's total loss.

Mullen Automotive shares slid on Friday morning after plunging over 26% in the previous session, as&nbsp;investors responded negatively to the EV maker’s 1-for-60 reverse stock split&nbsp;announcement.&nbsp;The move aims to help Mullen regain compliance with Nasdaq’s $1 minimum bid price rule. The split will take effect on Feb. 18.On Stocktwits, Mullen’s sentiment meter shifted to ‘neutral’ from ‘bullish’ amid increased message volume.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MULN_sentiment_Feb_14_4cf83233f7.png" alt="MULN sentiment Feb 14.png" width="1318" height="324"><figcaption>MULN sentiment and message volume on Feb 14 as of 10:00 am ET | source: Stocktwits</figcaption></figure>Bearish posts pointed to reports of a legal setback: Mullen lost a lawsuit against GEM Group, which it had accused of unregistered securities dealing and market manipulation.&nbsp;<stembedurl>https://stocktwits.com/KendallP/message/604248065</stembedurl>A court&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://storage.courtlistener.com/recap/gov.uscourts.nysd.615724/gov.uscourts.nysd.615724.148.0.pdf">filing</a> confirmed the ruling against Mullen, ordering the company to pay over $26 million in damages plus interest within 90 days — a sum that bearish retail traders noted far exceeds the EV maker’s current market capitalization and annual revenue.Mullen only recently moved from pre-revenue development to commercial EV sales, reporting $400,000 in revenue for fiscal 2023 and about $1.1 million in fiscal 2024.&nbsp;However, its net loss for the twelve months ended Sept. 30, 2024, widened as non-cash impairment charges climbed to $119.2 million from $84.6 million the prior year.&nbsp;The company&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/01/24/3015112/0/en/Mullen-Reports-Improved-2024-Financial-Results.html">cited</a> ongoing funding challenges and a sharp decline in its market cap as key drivers of the charge.Cash and equivalents dropped to $10.3 million from $155.3 million a year earlier, while total debt stood just below $20 million.Still, some bullish traders speculated that Mullen’s upcoming quarterly earnings report could trigger a rebound, suggesting the reverse split was strategically timed ahead of the release.&nbsp;<stembedurl>https://stocktwits.com/DEDBEARS/message/604286050</stembedurl>The company has also seen some recent positive developments, including last month’s purchase of battery line equipment from Nikola for its Fullerton facility and new orders for its electric cargo vans from universities in Los Angeles and the San Francisco Bay Area.Earlier this year, Mullen reported better-than-expected road testing&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://electrek.co/2024/02/29/mullen-sees-better-than-expected-road-testing-results-from-energy-dense-solid-state-batteries/">results</a> for its solid-state batteries, showing promising gains in driving range.&nbsp;Founded in 2014, the company initially sought to revive a defunct EV model before pivoting to develop its vehicles.&nbsp;After a 2020 merger, Mullen <a href="https://stocktwits.com/news-articles/markets/equity/muln-stock-dips-after-cost-cut-plans/cJcQXH5REP">acquired</a> a majority stake in Bollinger Motors in 2023 and bought assets from bankrupt Electric Last Mile Solutions.Despite these efforts, investors remain cautious as Mullen navigates legal hurdles and financial strain.&nbsp;The stock has lost over 99% of its value in the past year, with the upcoming earnings report on Feb. 17 seen as a key test for the company’s growth narrative.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In 2022, Mullen spent $148 million acquiring Bollinger Motors and another $240 million on Electric Last Mile Solutions. Photo courtesy: Mullen

Mullen Automotive Stock In Reverse Gear On 1-For-60 Reverse Split Plan: Retail Sentiment Mixed

The stock has lost over 99% of its value in the past year, with the upcoming earnings report on Feb. 17 seen as a key test for the company’s growth narrative.

Shares of Candel Therapeutics Inc.&nbsp;(CADL)&nbsp;surged over 9% on Friday morning, reaching their highest level in nearly a month and setting the stage for their best weekly gain (+20%) since Dec. 20.BofA Securities initiated coverage of Candel with a 'Buy' rating and a $15 price target, according to The Fly, implying an upside of about 92% from the previous close.&nbsp;The brokerage highlighted promising early data for Candel's two lead drug candidates —&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/cadl-stock-soars-after-prostate-cancer-drug-trial-data/cJa3iD5R0a">CAN-2409</a> and CAN-3110 — as key drivers of its bullish outlook.The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.&nbsp;BofA added that CAN-3110 has shown early indications of nearly doubling overall survival in patients with recurrent high-grade glioma.Last month, Candel provided a broad update on what to expect this year and beyond:<ul style="list-style-type:circle;"><li>Q1 2025: Updated overall survival data from Phase 2a clinical trials of CAN-2409 in pancreatic ductal adenocarcinoma and non-small cell lung cancer.</li><li>Q4 2025: Phase 1b overall survival data for CAN-3110 in patients with recurrent high-grade glioma.</li><li>Q4 2026: Biologics License Application (BLA) submission for CAN-2409 in prostate cancer.</li><li>Upcoming scientific conferences: Presentation of Phase 3 data for CAN-2409 in prostate cancer.</li></ul>Candel also disclosed that its cash and cash equivalents stood at approximately $103 million as of&nbsp;Dec. 31, 2024, which the company expects to fund its operations into the first quarter of 2027.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CADL_sentiment_and_message_volume_Feb_7_0ea124a0a6.png" alt="CADL sentiment and message volume Feb 7.png" width="1318" height="324"><figcaption>CADL sentiment and message volume Feb 7 as of 11 am ET | source: Stocktwits</figcaption></figure>Stocktwits sentiment on Candel flipped to ‘bullish’ (71/100) on Friday from a ‘bearish’ (42/100) reading last week, amid a spike in message volume.&nbsp;Retail traders cheered BofA's bullish rating, with one urging investors to stay long on the stock.<stembedurl>https://stocktwits.com/LongLTC/message/603284668</stembedurl>Adding to the optimism, a retail investor flagged a 13G&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/315066/000031506625000400/xslSCHEDULE_13G_X01/primary_doc.xml">filing</a> from Fidelity Investments on Friday, revealing that it now owns a 9.3% stake in Candel.<stembedurl>https://stocktwits.com/jzellner/message/603322436</stembedurl>Notably, according to Koyfin data, short interest in Candel stock dropped from 14.1% at the beginning of January to 6.9% by the end of the month.<a href="https://stocktwits.com/symbol/CADL">Candel shares</a> have skyrocketed 560% over the past 12 months — and with bullish sentiment building, some traders believe the rally is far from over.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Photo caption: BofA’s $15 price target implies an upside of about 92% from the previous close. | Image source: Getty Images

Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call

The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.

HDG
ProShares Hedge Replication ETF

Feed

News

Sentiment

Fundamentals

Info

Latest HDG News

HDG ProShares Hedge Replication ETF